Health News
Nov 20th, 2026

A NEW SHOT AGAINST THE DEADLIEST BITE: Europe Approves Sanofi's Next-Generation Rabies Vaccine for All Ages

Written By | Health News Agencies
VaxRabeo, cleared by the European Commission for both pre- and post-exposure protection, lasts five years on the shelf and survives four days at room temperature.

VaxRabeo, cleared by the European Commission for both pre- and post-exposure protection, lasts five years on the shelf and survives four days at room temperature. Experts say those features could matter most in the places where rabies still kills about 59,000 people a year.

 

PARIS 

It starts with a nip from a stray dog, a scratch from a jumpy monkey at a tourist temple, or a bat brushing past in the night. Weeks or months later come fever, then agitation, then a terror of water, then death. Once symptoms appear, rabies is almost always fatal.

Yet it is also one of the most preventable deaths on Earth, provided the right vaccine reaches the right person in time. This week Europe took a step to make that more likely.

French drugmaker Sanofi announced on November 19, 2026, that the European Commission has approved VaxRabeo, its next-generation rabies vaccine, for both pre-exposure prophylaxis (PrEP), protection before any contact with the virus, and post-exposure prophylaxis (PEP), the emergency shots given after a bite. The approval covers all age groups, from young children to older adults.

It is the first marketing authorization anywhere in the world for VaxRabeo. It follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), adopted on September 17, 2026.

Sobi Q3FY27 Results: Revenue up 16% to SEK 9,124 M

A Killer Hiding in Plain Sight

Many people in Europe and North America think of rabies as a historical disease, something from Victorian novels or old Westerns. The numbers say otherwise. 
According to World Health Organization estimates cited by Sanofi, rabies is present in 150 countries and kills about 59,000 people every year. That is roughly one death every nine minutes. Around 29 million people receive post-exposure vaccination each year after being bitten or scratched by an animal that might be rabid.

The victims are disproportionately young. About 40% of people bitten by suspected rabid animals are children under 15, often because they play with dogs, are bitten on the face and hands, and may not tell an adult about a minor-looking bite.

Dogs are responsible for the vast majority of human cases. The burden falls hardest on rural communities in Africa and Asia, where stray dog populations are large, clinics may be hours away, and vaccines and rabies immunoglobulin are often scarce or expensive. 
Travelers are not immune either. Sanofi cites data suggesting that roughly 0.4% of travelers to rabies-endemic regions are exposed for every month they stay. For a backpacker spending six months in South or Southeast Asia, that adds up to a real risk.

What Is VaxRabeo?

VaxRabeo is an inactivated vaccine, meaning it contains rabies virus that has been killed and cannot cause infection. It uses the Wistar strain of the virus and is produced using Vero-cell technology, a well-established cell line used for vaccine manufacturing for decades.

It is not a radically new approach. It shares the same viral strain as Sanofi's existing rabies vaccines, Verorab and Imovax Rabies, which together have more than five decades of safety and effectiveness data behind them. Think of it as a refined successor rather than a brand-new experiment.

What has changed is the practical side. Sanofi says VaxRabeo has been formulated to minimize the risk of allergic reactions. It has a shelf life of 60 months, five full years, and improved thermostability compared with the company's current rabies vaccines. Before it is reconstituted for injection, it can remain stable at temperatures up to 27 degrees Celsius for 96 hours.

That last detail may sound technical, but it could be one of the most important features of the vaccine. Keeping vaccines cold, the so-called cold chain, is one of the biggest headaches in global health. A vaccine that can survive four days at warm room temperature is far easier to move from a city warehouse to a rural clinic without being spoiled by a broken fridge or a power cut.

The Schedules: Fewer Shots, Same Protection

The European approval covers several regimens. For pre-exposure protection, VaxRabeo is approved on the reduced two-dose schedule now recommended by the WHO. Both two-dose and three-dose regimens were studied. This is the option for travelers, veterinarians, laboratory workers, wildlife handlers and others at ongoing risk.

For post-exposure protection, people who have never been vaccinated receive four doses, with or without rabies immunoglobulin, the antibody treatment given for more serious exposures. 
A booster can be given 12 months or 24 to 36 months after the last pre-exposure dose, and Sanofi reports "high boostability," meaning the immune system responds strongly when reminded.

What the Trials Showed

Sanofi says VaxRabeo was tested in a comprehensive clinical program comparing it head to head with Verorab and Imovax Rabies in both pre- and post-exposure settings, across all age groups and WHO-recommended schedules.

In pre-exposure trials, VaxRabeo produced protective antibody levels comparable to the established vaccines in adults and children, on both the two-dose and three-dose schedules. In post-exposure trials, it showed a similar immune response profile to Sanofi's current standard-of-care vaccines, whether given alone or with rabies immunoglobulin. The company says all participants reached protective antibody levels after intramuscular injection.

On safety, Sanofi reports that VaxRabeo was well tolerated, with an acceptable safety profile similar to existing vaccines and no significant safety concerns, either alone or when combined with immunoglobulin. 
The company's announcement did not publish detailed figures such as participant numbers or exact antibody levels. Those details will be watched closely by doctors and health agencies as full data appear in medical journals and regulatory documents.

Expert Perspective: "Entirely Preventable"

Thomas Triomphe, Head of Vaccines at Sanofi, framed the approval in stark terms. "Death from rabies should be prevented at all costs; it is entirely preventable with vaccination provided on time," he said. 
He called the decision "a proud milestone for Sanofi" and said the vaccine was "built on five decades of expertise and innovation." He added: "With VaxRabeo, we are bringing a next-generation rabies vaccine to healthcare systems and patients."

The bigger picture is a global target. In 2018, the WHO, the Food and Agriculture Organization of the United Nations, the World Organisation for Animal Health and the Global Alliance for Rabies Control launched "Zero by 30," a strategic plan to end human deaths from dog-mediated rabies by 2030. With barely four years left, progress has been uneven. Some countries, especially in Latin America, have made huge gains through mass dog vaccination, while much of Africa and Asia remains far off track.

Public health specialists have long argued that rabies control rests on two pillars: vaccinating dogs to stop the virus at its source, and making sure every bitten person can get prompt post-exposure treatment. Human vaccines that are easier to store, ship and stock in remote clinics directly support that second pillar.

EU Approves VaxRabeo Rabies Vaccine for All Ages | Wisevoter

The Questions Still Hanging

For now, VaxRabeo is approved only in the European Union. Sanofi's announcement did not mention approvals elsewhere, nor did it give a price or a date when the vaccine will reach pharmacies and travel clinics.

The places where rabies kills the most people are mostly outside Europe. Whether VaxRabeo makes a dent in the global death toll will depend on regulatory approvals in Africa and Asia, WHO prequalification, which allows United Nations agencies and global funders to buy a vaccine, and above all on price and supply.

There is also the stubborn problem of awareness. Many rabies deaths happen not because no vaccine exists but because families do not know a dog bite is an emergency, cannot afford the trip to a clinic, or arrive to find the shelves empty. A better vaccine helps only if it is in the right place and people know to ask for it.

What This Means for You

If you are traveling to Africa, Asia, Latin America or other places where rabies is common, talk to a travel clinic about pre-exposure vaccination, especially for long trips, rural travel, cycling, trekking, caving or work with animals. Pre-exposure shots do not remove the need for treatment after a bite, but they simplify it and remove the need for scarce immunoglobulin.

If you are bitten or scratched by a dog, cat, monkey, bat or other mammal where rabies may be present, act immediately. Wash the wound thoroughly with soap and running water for at least 15 minutes. This simple step can sharply reduce the risk of infection. Then seek medical care the same day for assessment and post-exposure vaccination. Do not wait for symptoms; by then it is too late.

Treat bat contact seriously, even when no obvious bite is visible. Bat bites can be tiny.

Vaccinate your pets. Dogs and cats vaccinated against rabies protect both themselves and their owners, and in high-risk countries mass dog vaccination is the single most effective way to stop human deaths. 
Teach children to tell an adult about any animal bite or scratch, no matter how small, and to avoid stray or unfamiliar animals.

The Bottom Line

More than a century after Louis Pasteur first used a rabies vaccine on a bitten boy in 1885, the disease still kills tens of thousands of people every year, most of them children, almost all of them in poorer countries. The tragedy is that nearly every one of those deaths could have been prevented.

VaxRabeo is not a miracle cure. It is a refined version of a vaccine that already works. But a five-year shelf life, four days of stability at room temperature, a simplified two-dose pre-exposure schedule and approval for every age group are the kinds of improvements that can carry protection further down a dusty road.

Europe has signed off. The real test is whether this next-generation shot reaches the villages, clinics and children who need it most before the 2030 deadline runs out.

Published By | Features Editor

More Related News